Why Teva’s new tardive dyskinesia data matters for shareholders Teva Pharmaceutical Industries (NYSE:TEVA) has put its neuroscience work in the spotlight by releasing new real world data from the ...

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — ...

Real-World Evidence of Positive Impact of LYBALVI® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse ...

Teva Pharmaceutical Industries (NYSE:TEVA) released new real world data from its IMPACT-TD Registry on tardive dyskinesia in ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mild tardive dyskinesia ...

New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood ...

New analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of ageThe d ...

Treatment for tardive dyskinesia (TD), a condition affecting the nervous system that causes uncontrollable body movements which can be triggered by antipsychotics or other medications that affect the ...

Once upon a time, Teva Pharmaceutical Industries Ltd. (TEVA +2.32%) was a stock that many investors didn't want to touch with a 10-foot pole. The pharmaceutical company faced lega ...

Tardive dyskinesia (TD) and related drug-induced movement disorders represent a spectrum of involuntary hyperkinetic and hypokinetic syndromes arising predominantly from long-term exposure to dopamine ...

Tardive dyskinesia stigma can negatively impact your life, but experts say there are a number of ways to lessen its effects.

Neurocrine Biosciences Inc. company and executive profile by Barron's. View the latest NBIX company infomation and executive bios.